¿¬±¸µ¿ÇâÁ¤º¸
Á¦¸ñ Á¦2Çü ´ç´¢º´ ȯÀÚ¿¡¼­ ÇÁ·Î¹ÙÀÌ¿Àƽ½º°¡ Ç÷´ç°­ÇÏÈ¿°ú¸¦ ³ªÅ¸³¾ ¼ö ÀÖ½À´Ï±î?
±Û¾´ÀÌ °ü¸®ÀÚ
÷ºÎÆÄÀÏ

 Á¦2Çü ´ç´¢º´ ȯÀÚ¿¡¼­ ÇÁ·Î¹ÙÀÌ¿Àƽ½º°¡ Ç÷´ç°­ÇÏÈ¿°ú

ÀÓ»óÁú¹®

Á¦2Çü ´ç´¢º´È¯ÀÚ¿¡¼­ ÇÁ·Î¹ÙÀÌ¿Àƽ½º°¡ Ç÷´ç°­ÇÏ È¿°ú¸¦ ³ªÅ¸³¾ ¼ö ÀÖ½À´Ï±î?

±Ù°Å±â¹Ý ´äº¯

ÇÁ·Î¹ÙÀÌ¿Àƽ½º Åõ¿©±º¿¡¼­´Â FBG°¡ ÀÇ¹Ì ÀÖ°Ô ³·¾Æ¼­ ÇÁ·Î¹ÙÀÌ¿Àƽ½º¿¡ Ç÷´ç°­ÇÏ È¿°ú°¡ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

¼­ÁöÁ¤º¸

Probiotics for the management of type 2 diabetes mellitus: A systematic review and meta-analysis.(2016). Samah S, Ramasamy K, Lim SM, Neoh CF, Diabetes research and clinical practice.118, 172-182.

http://www.epistemonikos.org/documents/9f18191d7306b498aad6e3e2646e0ea97f6e61e7

¿¬±¸¸ñÀû

¿¬±¸ÀÇ ¸ñÇ¥´Â Á¦2Çü ´ç´¢º´(T2DM)¿¡ ÇÁ·Î¹ÙÀÌ¿Àƽ½º(probiotics) Ä¡·á¿Í °ü·ÃµÈ Áõ°Å¸¦ ü°èÀûÀ¸·Î °íÂûÇÏ¿©, ÇÁ·Î¹ÙÀÌ¿Àƽ½º°¡ T2DM ȯÀÚµéÀÇ Ç÷´çÁ¶Àý È¿°ú¸¦ ºÐ¼®Çϴµ¥ ÀÖ½À´Ï´Ù.

¿¬±¸¼³°è

ü°èÀû °íÂû°ú ¸ÞŸºÐ¼®(Systematic Review & Meta analysis)

Áúȯ ¹× ¿¬±¸´ë»ó

18¼¼ ÀÌ»óÀÇ ¼ºÀÎ Á¦ 2Çü ´ç´¢º´È¯ÀÚ

½ÃÇ豺 ÁßÀç

ÇÁ·Î¹ÙÀÌ¿Àƽ½º¸¦ »ç¿ëÇÏ´Â ±º(ĸ½¶, ¿ä°ÅÆ® ÇüÅ µî)

´ëÁ¶±º ÁßÀç

Çö󼼺¸

Æò°¡ÁöÇ¥

1Â÷ Æò°¡ ÁöÇ¥ : HbA1c and FBG

2Â÷ Æò°¡ ÁöÇ¥ : fasting plasma insulin, homeostasis model assessment of insulin resistance (HOMA-IR), inflammatory markers [i.e. C-reactive protein (CRP), interleukin-6 (IL-6)], anti-oxidative or oxidative stress markers [i.e. malondialdehyde (MDA)]

ÁÖ¿ä°á°ú

Çö󼼺¸±º°ú ºñ±³ÇßÀ» ¶§ ÇÁ·Î¹ÙÀÌ¿Àƽ½º Åõ¿©±º¿¡¼­´Â FBG°¡ ÀÇ¹Ì ÀÖ°Ô ³·Àº °ÍÀ¸·Î ³ªÅ¸³µÁö¸¸(MD:-0.98mmol/L, 95%CI: -1.17~0.78, p<0.00001), ÀÌÁú¼ºÀÌ Å©°Ô °üÂûµÇ¾ú´ø Á¡ÀÌ ÁöÀûµÇ¾ú°í,  HbA1c³ª ´Ù¸¥ 2Â÷ Æò°¡ÁöÇ¥µé¿¡ ´ëÇؼ­´Â ½ÇÇ豺°ú ´ëÁ¶±º »çÀÌ¿¡ ÀÇ¹Ì ¾ø´Â Â÷À̸¦ º¸¿´½À´Ï´Ù.

±Ù°Å¼öÁØ

III (Moderate)

ÀÛ¼ºÀÚ

ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC)

Copyright © 2016. Medical Research Information Center (MedRIC) Editors




2017-10-23 ¿ÀÀü 9:16:20, Á¶È¸¼ö : 2757